Answers are grounded in this paper and cite their sources.
Asthma affects more than 300 million people worldwide1Global Asthma NetworkGlobal Asthma Report 2018.http://www.globalasthmareport.org/Global%20Asthma%20Report%202018.pdfDate accessed: March 25, 2020Google Scholar of whom approximately 10% have severe asthma.2Chung K.F. Wenzel S.E. Brozek J.L. et al.International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.Eur Respir J. 2014; 43: 343-373Crossref PubMed Scopus (1939) Google Scholar Up to 87% of patients with severe asthma have uncontrolled disease despite available inhaled therapies.3Chen S. Golam S. Myers J. Bly C. Smolen H. Xu X. Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment.Curr Med Res Opin. 2018; 34: 2075-2088Crossref PubMed Scopus (28) Google Scholar These patients experience frequent exacerbations, which can result in hospitalizations or emergency department (ED) visits, placing a burden on health care systems.3Chen S. Golam S. Myers J. Bly C. Smolen H. Xu X. Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment.Curr Med Res Opin. 2018; 34: 2075-2088Crossref PubMed Scopus (28) Google Scholar In the United States, asthma exacerbations account for approximately 1.8 million ED visits and 189,000 hospitalizations annually,4Centers for Disease Control and PreventionMost recent asthma data.https://www.cdc.gov/asthma/healthcare-use/healthcare-use-2016.htmDate accessed: March 25, 2020Google Scholar with a mean hospitalization cost of US $14,479 (2016).5Chastek B. Korrer S. Nagar S.P. et al.Economic burden of illness among patients with severe asthma in a managed care setting.J Manag Care Spec Pharm. 2016; 22: 848-861Crossref PubMed Scopus (63) Google Scholar Thus, there remains a major unmet need in the treatment of severe asthma that could be addressed through the development of therapies that successfully prevent the need for unplanned hospital care. Tezepelumab is a human monoclonal antibody (IgG2λ) that specifically blocks thymic stromal lymphopoietin from interacting with its receptor complex.6Corren J. Parnes J.R. Wang L. et al.Tezepelumab in adults with uncontrolled asthma.N Engl J Med. 2017; 377: 936-946Crossref PubMed Scopus (394) Google Scholar,7Gauvreau G.M. O’Byrne P.M. Boulet L.P. et al.Effects of an anti-TSLP antibody on allergen-induced asthmatic responses.N Engl J Med. 2014; 370: 2102-2110Crossref PubMed Scopus (517) Google Scholar Thymic stromal lymphopoietin is an upstream epithelium-derived cytokine released in response to inflammatory triggers and is critical to the initiation and persistence of airway inflammation in asthma.8Patel N.N. Kohanski M.A. Maina I.W. Workman A.D. De’Broski R.H. Cohen N.A. Sentinels at the wall: epithelial-derived cytokines serve as triggers of upper airway type 2 inflammation.Int Forum Allergy Rhinol. 2019; 9: 93-99Crossref PubMed Scopus (11) Google Scholar In the phase 2b PATHWAY study (Study to Evaluate the Efficacy and Safety of MEDI9929 [AMG 157] in Adult Subjects With Inadequately Controlled, Severe Asthma), tezepelumab significantly reduced exacerbations by up to 71% compared with placebo (P < .001) and improved lung function and asthma control in patients with severe, uncontrolled asthma.6Corren J. Parnes J.R. Wang L. et al.Tezepelumab in adults with uncontrolled asthma.N Engl J Med. 2017; 377: 936-946Crossref PubMed Scopus (394) Google Scholar In a previous analysis, tezepelumab-treated patients had fewer asthma exacerbation-related hospitalizations than those who received placebo.6Corren J. Parnes J.R. Wang L. et al.Tezepelumab in adults with uncontrolled asthma.N Engl J Med. 2017; 377: 936-946Crossref PubMed Scopus (394) Google Scholar To further our understanding of the treatment effects of tezepelumab, we evaluated its effect on the frequency and duration of hospitalizations, ED visits, and intensive care unit (ICU) visits. PATHWAY was a randomized, multicenter, double-blind, placebo-controlled study (ClinicialTrials.gov Identifier: NCT02054130). The full study design and inclusion and exclusion criteria have been described previously.6Corren J. Parnes J.R. Wang L. et al.Tezepelumab in adults with uncontrolled asthma.N Engl J Med. 2017; 377: 936-946Crossref PubMed Scopus (394) Google Scholar Eligible patients were current nonsmokers, aged 18 to 75 years, with severe asthma that was inadequately controlled despite treatment with medium-dose (250-500 μg/d of fluticasone dry powder inhaler or equivalent) or high-dose (>500 μg/d of fluticasone dry powder inhaler or equivalent) inhaled corticosteroids plus a long-acting β2-agonist. Patients were required to have experienced at least 2 asthma exacerbations that required systemic corticosteroids or at least 1 severe exacerbation that required hospitalization in the 12 months before study entry. Patients (N = 550) were randomized (1:1:1:1) to receive subcutaneous doses of tezepelumab 70 mg every 4 weeks (n = 138), 210 mg every 4 weeks (n = 137), or 280 mg every 2 weeks (n = 137), or placebo every 2 weeks (n = 138), for 52 weeks. The following data were recorded by the investigator at each study visit: asthma exacerbations that required hospitalizations (>24 hours in hospital); asthma exacerbations that required an ED visit (<24 hours in an ED); the number of all-cause hospital and ED visits; and the number of days spent in the hospital and in the ICU. Rate ratios and percentage reductions for individual and pooled tezepelumab dose groups vs placebo were estimated using a negative binomial model, with baseline peripheral blood eosinophil count (≥250 vs <250 cells/μL), baseline inhaled corticosteroid dose (medium vs high), and the corresponding baseline value for each event analyzed (number of events in the 12 months before treatment) as categorical covariates. Data on exacerbations that required an ED visit are reported descriptively owing to low numbers of patients with this event in each treatment group. Baseline demographics and clinical characteristics of the PATHWAY patient population have been reported previously and were similar across treatment groups.6Corren J. Parnes J.R. Wang L. et al.Tezepelumab in adults with uncontrolled asthma.N Engl J Med. 2017; 377: 936-946Crossref PubMed Scopus (394) Google Scholar Compared with placebo, treatment with tezepelumab led to a relative rate reduction in asthma exacerbations that required hospitalizations of up to 84% (nominal P < .05 in the 70 mg, 210 mg, and pooled tezepelumab groups; events per patient among those with events: placebo, 2.1; tezepelumab, 1.0) (Fig 1A) and a relative rate reduction in all-cause hospital visits of up to 73% (P < .05 in the 70 mg and pooled tezepelumab groups; events per patient among those with events: placebo, 2.4; tezepelumab, 1.1-1.6) (Fig 1B). The percentage of patients with asthma exacerbation–related ED visits in the tezepelumab groups (0.7% to 1.5%; 1.0 event per patient among those with events) was approximately half of that seen in the placebo group (3.6%; 1.4 events per patient among those with events) (Fig 1C). In addition, treatment with tezepelumab led to a relative rate reduction in all-cause ED visits of up to 84% compared with placebo (nominal P < .05 in the 210 mg and pooled tezepelumab groups; events per patient among those with events: placebo, 1.8; tezepelumab, 1.0-1.4) (Fig 1D). Among patients admitted to the hospital or the ICU, those treated with tezepelumab reported fewer mean days in the hospital and fewer mean days in the ICU compared with those who received placebo (Fig 1E and F). Treatment adherence and comorbidities (including those associated with oral corticosteroid therapy) were broadly similar among treatment groups and were not considered to have impacted the treatment effects of tezepelumab. Asthma exacerbation–related ED visits and inpatient stays are associated with high costs that increase with increasing disease severity and length of stay.9Suruki R.Y. Daugherty J.B. Boudiaf N. Albers F.C. The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA.BMC Pulm Med. 2017; 17: 74Crossref PubMed Scopus (95) Google Scholar This analysis found that tezepelumab reduced the rate of asthma exacerbations that required hospitalizations or ED visits over 52 weeks compared with placebo in patients with severe, uncontrolled asthma. Patients treated with tezepelumab spent fewer days in the hospital and fewer days in the ICU over the 52-week treatment period compared with those who received placebo. In addition, the frequency of all-cause hospital and ED visits was lower in patients treated with tezepelumab than in those who received placebo; these reductions reached nominal statistical significance in the pooled tezepelumab group. The reduction in all-cause hospitalizations seen after treatment with tezepelumab cannot be completely explained by the reduction in asthma exacerbation–related hospitalizations seen after treatment with tezepelumab. The ongoing phase 3 NAVIGATOR study (Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma) (ClinicalTrials.gov Identifier: NCT03347279), which has a larger study population than the PATHWAY phase 2b study, will help to determine whether this observed effect occurs consistently. Taken together, these data provide further evidence of the potential beneficial effects of tezepelumab in the treatment of patients with severe, uncontrolled asthma and indicate that blocking thymic stromal lymphopoietin is an effective strategy for the treatment of this disease. This finding is being further explored in ongoing phase 2/3 trials (NAVIGATOR; SOURCE [Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma] [ClinicalTrials.gov Identifier: NCT03406078]; and CASCADE [Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma] [ClinicalTrials.gov Identifier: NCT03688074]). We thank Kinga Sałapa for support with statistical analyses. Medical writing support was provided by Laura Knapp, PhD, of PharmaGenesis London, London, United Kingdom.
No takes yet. Share an insight, caveat, or question.
Corren et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: